주식/증권
📈 긍정적
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
요약
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.